FDA Inspection 1231440 — Hillcrest Medical Center-Irb
The FDA completed an inspection of Hillcrest Medical Center-Irb on Feb 14, 2024 in Tulsa, OK. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Feb 14, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Tulsa, OK (United States)
Additional Details
IRB